Reata Pharma (RETA) Misses Q4 EPS by 4c

Reata Pharma (NASDAQ: RETA) reported Q4 EPS of ($2.35), $0.04 worse than the analyst estimate of ($2.31). Revenue for the quarter came in at $934 thousand versus the consensus estimate of $1.63 million.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Helius Medical Technologies (HSDT) Misses Q2 EPS by 31c